

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-A**

---

**FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

---

**Apellis Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State of incorporation  
or organization)

**27-1537290**  
(I.R.S. Employer  
Identification No.)

**6400 Westwind Way, Suite A**  
**Crestwood, Kentucky**  
(Address of principal executive offices)

**40014**  
(Zip Code)

*Securities to be registered pursuant to Section 12(b) of the Act:*

**Title of each class  
to be so registered**

**Name of each exchange on which  
each class is to be registered**

---

Common stock, par value \$0.0001 per share

---

The Nasdaq Stock Market LLC

---

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A. (c) or (e), please check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A. (d) or (e), please check the following box.

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box.

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-220941**

Securities to be registered pursuant to Section 12(g) of the Act: **None.**

---

---

---

**Item 1. Description of Registrant's Securities to be Registered.**

The description under the heading "Description of Capital Stock" relating to the common stock, \$0.0001 par value per share, of Apellis Pharmaceuticals, Inc. (the "Registrant") in the prospectus included in the Registrant's Registration Statement on Form S-1 (File No. 333-220941), as amended (the "Registration Statement"), filed under the Securities Act of 1933, as amended (the "Securities Act"), with the Securities and Exchange Commission (the "Commission") is incorporated herein by reference. Any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act that constitutes part of the Registration Statement shall be deemed to be incorporated herein by reference.

**Item 2. Exhibits.**

Pursuant to the Instructions as to Exhibits for Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Apellis Pharmaceuticals, Inc.

Dated: November 3, 2017

By: /s/ David Watson

David Watson

General Counsel